What Eloxatin Treats: Main Uses and Benefits

This medicine is an established therapeutic option for the management of bowel cancer. It is generally applied across domains where additional symptomatic support and disease control are needed for serious conditions.

---

Systemic Management of Advanced Bowel Cancer

This medicine is primarily used for patients with advanced bowel cancer, including cases where the condition has spread to distant sites. Its use plays a role in managing symptoms that interfere with daily functioning by supporting control of the growth and spread of the condition, which contributes to overall disease support. It may also assist with maintaining functional stability by managing symptoms related to physical discomfort and organ-specific functional stress.

“This medicine is commonly used to help with achieving stabilization of the disease in challenging clinical presentations.”

Adjuvant Therapy for High-Risk Conditions

Eloxatin is commonly used in the adjuvant setting following surgery for conditions associated with a high risk of recurrence. In this context, it is applied to address the potential for fluctuating manifestations. Its use plays a role in managing the overall symptom load by supporting the reduction of the risk of the condition returning, and may assist with maintaining functional stability by supporting a better long-term prognosis. This therapeutic strategy is also relevant for conditions presenting with systemic or localized discomfort in other related gastrointestinal areas.

Quick Fact: Relief for Disease Burden
This medicine supports patients facing conditions marked by increased physiological stress, providing support that helps ease the overall symptom burden caused by the underlying condition.

Eloxatin (Oxaliplatin) use is restricted to the adult patient population as its safety and effectiveness have not been established in the pediatric population.

Contraindicated Populations (Must Not Use)

Official regulatory labeling dictates that Eloxatin is contraindicated in specific patient groups:

• Patients with a known history of hypersensitivity or allergic reaction to oxaliplatin or any other platinum-containing compounds.
• Women who are breastfeeding.
• In some regulatory regions, patients with severe renal impairment (creatinine clearance < 30 mL/min) or significant pre-treatment myelosuppression are also contraindicated.

---

Restricted and Conditional Use

• Pregnancy: Use is generally not recommended due to the potential for embryo-fetal toxicity. Effective contraception must be used by both male and female patients of reproductive potential during and for a specified time after treatment.
• Organ Function: Patients with pre-existing mild to moderate renal impairment or certain cardiac conditions (e.g., predisposition to QT interval prolongation) require close monitoring and may need dose adjustments or avoidance.
• Older Adults: While no dose adjustment is required for patients 65 years and older based on age alone, this population is monitored for potentially increased unwanted effects.

Eloxatin Interactions with Other Medicines and Products

The official interaction profile for Eloxatin (Oxaliplatin) is established through its chemical constraints, administration requirements, and documented additive toxicity risks. Factual statements confirm that the drug is not metabolized by, nor does it inhibit or induce, major human cytochrome P450 enzymes. Consequently, CYP-mediated drug-drug interactions are not anticipated based on current regulatory data.

---

Mandatory Restrictions and Incompatibilities

• Re-administration is strictly prohibited in patients with a documented history of severe hypersensitivity or allergic reaction to Oxaliplatin or any other platinum compound.
• The drug solution is chemically incompatible and must not be mixed or administered simultaneously through the same infusion line with alkaline medicinal products or media, such as certain preparations of 5-Fluorouracil or Leucovorin.
• The Eloxatin infusion must always precede the administration of 5-Fluorouracil or other fluoropyrimidines when co-administered, establishing a mandatory sequence.

---

Documented Exposure and Toxicity Risks

Additive effects and clearance changes define other documented interactions:

• Additive Toxicities: Caution is warranted with co-administration of medicines known to prolong the QT interval or those with specific neurological toxicity due to the potential for additive pharmacodynamic effects on the heart or nervous system.
• Exposure Changes: Co-administration of nephrotoxic products is discouraged because the drug’s primary renal elimination means decreased kidney function can lead to increased systemic platinum exposure. Official labeling notes that in patients with severe renal impairment, exposure to unbound platinum is significantly increased.

Eloxatin, which is oxaliplatin, functions as a platinum-based alkylating agent that targets nuclear DNA. Upon intravenous administration, the labile oxalate ligand is nonenzymatically displaced in physiologic solution, generating transient, highly reactive platinum species, including monoaquo and diaquo DACH platinum intermediates.

These active derivatives covalently bind to DNA, primarily at the N7 positions of guanine residues, forming platinum-DNA adducts. The predominant interaction type is intrastrand cross-linking between adjacent guanine-guanine (GG) base pairs, although interstrand and DNA-protein cross-links also occur. The formation of these bulky adducts inhibits both DNA replication and transcription, leading to a cellular stress response. This blockage of key intracellular processes activates the intrinsic apoptotic pathway, characterized by the translocation of the pro-apoptotic protein Bax to the mitochondria and the subsequent release of cytochrome C into the cytosol. The downstream cascade culminates in the activation of caspase-3, initiating the programmed cell death of the target cell. System-level physiological consequences involve the reduction of cellular proliferation and a net decrease in the viable population of fast-dividing cells.

Eloxatin (Oxaliplatin) is administered exclusively as an intravenous (IV) infusion under the supervision of a physician experienced in cancer treatment. The usage pattern is highly standardized and defined by strict protocols.

---

Administration Schedule and Dosage

The standard administration involves receiving a dose of 85 mg/ m^2 (milligrams per square meter of body surface area) on Day 1 of a 14-day cycle. This medicine must be administered as part of a combination regimen that typically includes 5-fluorouracil (5-FU) and leucovorin. A critical procedural rule requires that the Eloxatin infusion must always precede the infusion of the fluoropyrimidines. The duration of the infusion is typically 120 minutes (2 hours), though the infusion period may be extended up to six hours.

---

Preparation and Procedural Constraints

Prior to administration, the medicine must be diluted only in a 5% Dextrose Injection, USP solution. Specific protocols prohibit dilution with sodium chloride or other chloride-containing solutions. Furthermore, to prevent the degradation of the active ingredient, the use of intravenous sets or needles containing aluminum parts is restricted. Treatment duration depends on the clinical context; for instance, in the adjuvant setting, it is commonly continued for up to 12 cycles (6 months).

---

Population Adjustments

Dose adjustments are specified for certain patient populations. For individuals with severe renal impairment (kidney function changes), the initial dose is reduced to 65 mg/ m^2. No specific initial dose adjustment is required for patients over 65 years of age.

Recent Clinical Evidence for Eloxatin (Oxaliplatin)

Eloxatin, known by its generic name oxaliplatin, is a platinum-based chemotherapy medication primarily studied and used in the management of colorectal cancer. It is a core component of combination regimens, most commonly with fluorouracil (5-FU) and leucovorin (FOLFOX).

Efficacy in Colorectal Cancer

Clinical trials have established oxaliplatin's role in two main settings for colorectal cancer:

• Adjuvant Treatment: Studies have demonstrated that adding oxaliplatin to fluoropyrimidine-based chemotherapy for patients with resected Stage III colon cancer reduces the risk of cancer recurrence compared to fluoropyrimidine alone. The full recommended treatment period for this setting is typically 12 cycles.
• Advanced or Metastatic Colorectal Cancer: In patients with advanced disease, oxaliplatin combinations are used as part of first-line treatment. Data from randomized trials indicate that the addition of oxaliplatin to 5-FU/leucovorin increases the overall response rate and time to tumor progression compared to the two-drug combination alone.

Ongoing Research and Specific Populations

Recent research continues to refine the use of oxaliplatin by focusing on specific patient needs and safety. One area of investigation involves optimizing chemotherapy duration for Stage III disease, where studies have explored shorter courses (e.g., three months) versus the standard six months to manage the risk of side effects.

Studies have also examined the outcomes of oxaliplatin in older adults, suggesting that while it may be associated with improved survival in patients aged 70 and younger with Stage III disease, the benefit may be less clear or associated with increased toxicity in patients over 70. This highlights the importance of individual risk assessment.

Common questions about Eloxatin (FAQ)

---

Q: How quickly does Eloxatin start working?

According to official product information, once administered, the drug quickly undergoes a nonenzymatic conversion to form active platinum species. These active components are then rapidly distributed throughout the body. While the drug is quickly present in the system, its full mechanism relies on sustained exposure over the course of the treatment regimen.

Q: How long do the effects of Eloxatin last in the body?

The drug's platinum components are cleared from the plasma relatively quickly, but total unbound platinum in the body is eliminated slowly over a period of weeks. Platinum also accumulates and is cleared from red blood cells over a much longer duration. This long clearance time means the drug's effects can last in the system well after administration.

Q: Is Eloxatin used for cancer types besides colorectal cancer?

Official regulatory documents confirm that Eloxatin is indicated only for the adjuvant treatment of Stage III colon cancer after surgery and for the treatment of metastatic colorectal cancer. The use of the drug is strictly limited to the specific indications where its effectiveness and safety have been demonstrated in clinical trials.

Q: What is the difference between Eloxatin and other platinum-based drugs?

Eloxatin is categorized as a third-generation platinum compound. It differs from older drugs like cisplatin or carboplatin by having a unique chemical feature called a diaminocyclohexane (DACH) ligand. Official documents state that this specific structure contributes to its activity and may allow it to work against cancer cells that are resistant to other platinum medicines.

Q: Why does Eloxatin sometimes cause sensitivity to cold?

This side effect is a common manifestation of peripheral neuropathy, which is an effect on the nerves. Regulatory documents state that these nerve effects, which may include tingling, numbness, or cramping, are often triggered or exacerbated by exposure to cold, such as opening a refrigerator or holding a cold drink, and are a manifestation of peripheral neuropathy.

Q: Are there any long-term health concerns associated with Eloxatin?

A known potential long-term concern is the possibility of persistent symptoms of peripheral sensory neuropathy (nerve effects) after the end of treatment. There is also a warning that the drug may have an antifertility effect that could be irreversible. The regulatory documents require that information about these potential long-term effects, including antifertility risks, be provided to patients.

Q: Can Eloxatin affect fertility?

Yes, regulatory warnings state that Eloxatin may have an antifertility effect, and this effect could be irreversible. Regulatory documents state that effective contraception is required for both male and female patients of reproductive potential during and for a specified period after treatment.

Q: What kind of monitoring is done while taking Eloxatin?

Official product information specifies that patients should be regularly monitored. This monitoring includes a full blood count (to check white blood cells and platelets), liver function tests, and a neurological examination (to check for nerve effects) before each administration.

Q: What happens if a dose of Eloxatin is missed or delayed?

If certain toxicities occur—such as low blood counts, severe gastrointestinal issues, or troublesome nerve symptoms—the administration of the next dose will be postponed. The decision to administer the dose is based on the patient’s lab values and symptom resolution meeting acceptable clinical levels, as defined in the treatment protocol.

Q: Does Eloxatin interact with common pain relievers?

Official documents advise caution regarding co-administration with other medicines. Specifically, this includes drugs known to cause QT interval prolongation (a heart rhythm effect) or those with specific neurological toxicity, due to the potential for additive effects. The drug is also chemically incompatible with alkaline products.

Q: Why is Eloxatin given on a specific schedule?

The specific schedule (typically given every two weeks) is based on the clinical trial protocols that established the drug's effectiveness and safety. This cycle length is designed to balance the drug's activity against the necessary recovery time for the body from potential toxicities, particularly effects on the bone marrow.

Q: Can Eloxatin cause changes to the skin or nails?

Yes, skin reactions are commonly reported side effects. These reactions can include a general skin disorder or rash, and may also include specific reactions like blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet.

Q: Is Eloxatin considered a high-risk drug?

Yes, Eloxatin is classified by regulatory authorities as a cytotoxic agent and a hazardous drug. The classification as a cytotoxic and hazardous drug means it requires special handling, administration, and disposal procedures by trained personnel to ensure safety.

Q: Does being overweight or underweight change how Eloxatin works?

Official product information states that the dose of Eloxatin is based on the patient's Body Surface Area ( m^2). This is a calculation that uses both the patient's height and weight. Therefore, the amount of medicine administered is directly adjusted based on these body measurements.

Q: Why is Eloxatin not used for all types of cancer?

Eloxatin is only approved for use in the treatment of specific types of colorectal cancer. Its official indications are strictly limited by regulatory authorities to the cancer types where its effectiveness and safety have been demonstrated in clinical trials.

Q: Is feeling dizzy a common side effect of Eloxatin?

Dizziness is a possible side effect of Eloxatin treatment. Official information carries a warning that if dizziness or other neurological symptoms that affect walking and balance occur, patients should not drive or operate machinery.

Q: Is the cold sensitivity temporary or permanent after treatment with Eloxatin?

The cold sensitivity is a sign of peripheral neuropathy. While the symptoms in the majority of cases eventually resolve completely, regulatory documents warn that there is a possibility that symptoms of this nerve damage may persist after the end of the treatment.

Q: Can a person drive or operate machinery after receiving Eloxatin?

Official information advises caution because Eloxatin treatment may increase the risk of dizziness, nausea, vomiting, or neurological symptoms that affect balance. If these effects occur, official product warnings state that operating machinery or driving is not recommended.

Q: Does Eloxatin cause hair loss?

Yes, hair loss (alopecia) is a documented side effect of Eloxatin. Clinical trials reported that hair loss occurred in a significant minority of patients.

Q: How long after stopping Eloxatin can a person expect side effects to fade?

The drug's most frequent and significant long-lasting effect, peripheral sensory neuropathy, is generally expected to be reversible a few months after stopping treatment. Other common side effects typically resolve with appropriate supportive care.

Q: What happens to Eloxatin in the body after it is administered?

Once administered, Eloxatin rapidly converts in the body to active platinum species. These components then bind irreversibly to plasma proteins. The major route of elimination for the platinum compounds is through renal excretion (via the kidneys).

Q: What official documents describe the drug's approved uses?

The official documents describing approved uses include the FDA Prescribing Information (Label) in the United States and the Summary of Product Characteristics (SmPC) issued by the European Medicines Agency (EMA). These documents contain the authoritative, regulated information on the drug.

Q: Is there a link between Eloxatin and hearing changes?

Yes, official documents acknowledge a documented risk of ototoxicity (hearing-related toxicity). Both hearing changes and deafness have been reported as side effects in clinical trial experience.

Official Storage and Disposal Requirements

Eloxatin (Oxaliplatin) must be stored and handled according to strict regulatory guidelines due to its classification as a cytotoxic and hazardous drug.

Storage Conditions

Requirement	Details
Temperature	Store unopened vials at Controlled Room Temperature (20 C to 25 C). Do not freeze.
Light	The concentrated solution must be protected from light by keeping it in the original outer carton.
Preparation	Must only be prepared with 5% Dextrose Injection (D5W) and must not be mixed with chloride solutions or aluminum devices.
Stability	The prepared (diluted) solution is stable for 6 hours at room temperature or up to 24 hours under refrigeration.

Handling and Disposal

Storage must include measures to store locked up to prevent accidental access. Handling requires the use of appropriate protective equipment by trained personnel. Disposal of any unused product or contaminated materials must follow special handling and disposal procedures for hazardous waste, ensuring the material is discarded at an approved disposal plant and not poured down drains or sewers.